[Molecular pathogenesis of lung cancers and the preservative therapy].
Shimizu
Eiji
E
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis / Q000235:genetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000517:prevention & control / Q000628:therapy*; D018288:Carcinoma, Small Cell / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy*; D018797:Cell Cycle Proteins / Q000235:genetics; D002945:Cisplatin / Q000008:administration & dosage; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005047:Etoposide / Q000008:administration & dosage; D000077156:Gefitinib; D018390:Gene Targeting; D019254:Genes, bcl-2 / Q000235:genetics; D016158:Genes, p53 / Q000235:genetics; D015316:Genetic Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy*; D008403:Mass Screening; D009154:Mutation; D017239:Paclitaxel / Q000008:administration & dosage; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant
D018797:Cell Cycle Proteins; D004791:Enzyme Inhibitors; D011799:Quinazolines; D005047:Etoposide; D011505:Protein-Tyrosine Kinases; D017239:Paclitaxel; D002945:Cisplatin; D000077156:Gefitinib